Sasanuma H, Tsuda M, Morimoto S, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc Natl Acad Sci U S A. 2018;115(45):E10642-E10651. doi:10.1073/pnas.1803177115.

Haggarty SJ, Koeller KM, Kau TR, Silver PA, Roberge M, Schreiber SL. Small molecule modulation of the human chromatid decatenation checkpoint. Chem Biol. 2003;10(12):1267-79.

Miller EL, Hargreaves DC, Kadoch C, et al. TOP2 synergizes with BAF chromatin remodeling for both resolution and formation of facultative heterochromatin. Nat Struct Mol Biol. 2017;24(4):344-352. doi:10.1038/nsmb.3384.

Zdraljevic S, Strand C, Seidel HS, Cook DE, Doench JG, Andersen EC. Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons. PLoS Genet. 2017;13(7):e1006891. doi:10.1371/journal.pgen.1006891.

Ben-David U, Cowell IG, Austin CA, Benvenisty N. Brief reports: Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha. Stem Cells. 2015;33(3):1013-9. doi:10.1002/stem.1888.

Madabhushi R, Gao F, Pfenning AR, et al. Activity-Induced DNA Breaks Govern the Expression of Neuronal Early-Response Genes. Cell. 2015;161(7):1592-605. doi:10.1016/j.cell.2015.05.032.

Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343(6166):80-4. doi:10.1126/science.1246981.

Basarab GS, Kern GH, McNulty J, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep. 2015;5:11827. doi:10.1038/srep11827.

Reck F, Alm R, Brassil P, et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity. J Med Chem. 2011;54(22):7834-47. doi:10.1021/jm2008826.